Advanced search
Publication Cover
Acta Cardiologica Volume 76, 2021 - Issue 1
Submit an article Journal homepage
272
Views
7
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Determinants of maximal dose titration of sacubitril/valsartan in clinical practice

Pieter Martensa Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;b Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3070-221XView further author information
ORCID Icon,
Lina Verluytena Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, BelgiumView further author information
,
Heleen Van de Broeka Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, BelgiumView further author information
,
Frauke Somersa Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, BelgiumView further author information
,
Jeroen Dauwa Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;b Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumView further author information
,
Matthias Duponta Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, BelgiumView further author information
&
Wilfried Mullensa Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;c Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumView further author information
 show all
Pages 20-29 | Received 11 Sep 2019, Accepted 22 Oct 2019, Published online: 07 Nov 2019

References

  • McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
  • McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16(7):817–825.
  • Martens P, Belien H, Dupont M, et al. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail. 2018;5(3):275–283.
  • Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–1184.
  • Maggioni AP, Orso F, Calabria S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016;18(4):402–410.
  • Greene SJ, Fonarow GC, DeVore AD, et al. Longitudinal titration of medical therapy for heart failure with reduced ejection fraction: CHAMP-HF registry. J Am Coll Cardiol. 2019;73(19):2365–2383.
  • Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–366.
  • DeVore AD, Hill CL, Thomas L, et al. Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the united states. Circ Heart Fail. 2018;11(9):e005400.
  • Wachter R, Viriato D, Klebs S, et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad Med. 2018;130(3):308–316.
  • Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588–597.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
  • Martens P, Verbrugge FH, Nijst P, et al. Changes in loop diuretic dose and outcome after cardiac resynchronization therapy in patients with heart failure and reduced left ventricular ejection fractions. Am J Cardiol. 2017;120(2):267–273.
  • Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–155.
  • Martens P, Vercammen J, Ceyssens W, et al. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. ESC Heart Fail. 2018;5(4):562–569.
  • Martens P, Lambeets S, Lau CW, et al. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions. Acta Cardiol. 2019;74(2):115–122.
  • Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol. 2019;108(10):1074–1082.
  • Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
  • Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193–1202.
  • Martens P, Belien H, Dupont M, et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36(4):e12435.
  • Mullens W, Martens P. Sacubitril/valsartan to reduce secondary mitral regurgitation. Circulation 2019;139(11):1366–1370.
  • Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–691.
  • Ter Maaten JM. Unravelling the effect of sacubitril/valsartan on loop diuretic dosing. Eur J Heart Fail. 2019;21(3):342–344.
  • Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019;21(3):337–341.
  • Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–1234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.